James S. Scibetta

Mr. Scibetta became a Director of Matinas BioPharma in November 2013.

He is the CEO of Maverick Therapeutics, Inc., a clinical-stage immuno-oncology company and a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”). Mr. Scibetta is also an Operating Partner at Takeda Ventures, Inc. Mr. Scibetta joined Maverick as CEO in 2017, where he led and oversaw its growth from start-up through the advancement of the industry’s first conditionally active bispecific T cell engager into human clinical development, and ultimately to the April 2021 acquisition by Takeda for up to $525 million.

Prior to joining Maverick, Mr. Scibetta was President of Pacira BioSciences (Nasdaq: PCRX), where he oversaw commercial and medical support activities, and directed commercial manufacturing and research. Mr. Scibetta also served as Pacira’s CFO where he led its 2011 initial public offering and subsequent debt and equity financings. Prior to that, Mr. Scibetta was an executive with Bioenvision Inc. (Nasdaq: BIVN) a commercial-stage oncology company acquired by Genzyme, and Merrimack Pharmaceuticals, an oncology-focused systems biology company.

Earlier in his career, he spent over a decade in investment banking where he was responsible for sourcing and executing transactions for a broad base of public and private healthcare and life sciences companies. He currently serves on the Board of Aquestive Therapeutics (Nasdaq: AQST). Mr. Scibetta received his Bachelor of Science in Physics from Wake Forest University and an MBA from the University of Michigan.